Search - tctmd.com

Displaying 41 - 60 of 117

Sort: Relevancy | Date

News Daily News

Rivaroxaban Offers Net Reduction in Fatal or Irreversible Events in ACS: ATLAS ACS-2 TIMI-51

Michael O'Riordan

July 06, 2018

News Daily News

Spin to Win: Results From Late-Breaking Meeting Trials Often Overstated

L.A. McKeown

May 15, 2018

News Features

ISCHEMIA Fracas: Amid Charges of Moving the Goalposts, Investigators Come Out Swinging

Michael O'Riordan

March 23, 2018

Presentation Controversies and Advances 2017

Does IMPROVE-IT and FOURIER. Confirm or Refute the LDL Hypothesis?

Presenter: Sanjay Kaul

November 16, 2017

Presentation Controversies and Advances 2017

Targeting Inflammation in Atherosclerosis: Has CANTOS Nailed It?

Presenter: Sanjay Kaul

November 16, 2017

Presentation TCT 2017

Flash Debate: Surgery Remains the First Option in All Operable Patients With Bicuspid Aortic Stenosis!

Presenter: Gilles Dreyfus, Sanjay Kaul, Alfredo Trento

November 01, 2017

Presentation TCT 2017

Flash Debate: Enough Evidence Is Present to Justify TAVR in Select Patients With Bicuspid Aortic Stenosis!

Presenter: Gilles Dreyfus, Sanjay Kaul, John G. Webb

November 01, 2017

Presentation TCT 2017

Flash Debate: Surveillance and Prophylactic Treatment of Asymptomatic TAVR Thrombosis Is Not Currently Warranted!

Presenter: Gilles Dreyfus, Sanjay Kaul, Hendrik Treede

November 01, 2017

Presentation TCT 2017

Flash Debate: Valve Thrombosis After TAVR Is a Serious Concern That Deserves Detection and Management!

Presenter: Gilles Dreyfus, Sanjay Kaul, Raj Makkar

November 01, 2017

Presentation TCT 2017

Flash Debate: Based on Clinical Studies, Embolic Protection Devices Should Infrequently Be Used During TAVR

Presenter: Gilles Dreyfus, Sanjay Kaul, Duane S. Pinto

November 01, 2017

Presentation TCT 2017

Flash Debate: The Evidence and Clinical Need Justifies the Widespread Use of Embolic Protection During TAVR

Presenter: Gilles Dreyfus, Sanjay Kaul, Samir R. Kapadia

November 01, 2017

Presentation TCT 2017

Flash Debate: Bioresorbable Scaffolds Are Appropriate for Clinical Use in Suitable Patients With Optimal Technique!

Presenter: Sanjay Kaul, Tullio Palmerini, Robert-Jan van Geuns

November 01, 2017

Presentation TCT 2017

Flash Debate: Bioresorbable Scaffolds Should Rarely be Used Outside of Carefully Controlled Research Studies!

Presenter: Sanjay Kaul, Tullio Palmerini, Robert A. Byrne

November 01, 2017

Presentation TCT 2017

Flash Debate: If Anything, Guideline Recommendations for PCI in Low-to-Intermediate Risk Left Main Disease Should be Downgraded Based on EXCEL and NOBLE!

Presenter: Sanjay Kaul, Tullio Palmerini, Jacek Legutko

November 01, 2017

Presentation TCT 2017

Flash Debate: Guideline Recommendations for PCI in Low-to-Intermediate Risk Left Main Disease Should Be Upgraded to Class I Based on EXCEL and NOBLE!

Presenter: Sanjay Kaul, Tullio Palmerini, Evald H. Christiansen

November 01, 2017

Presentation TCT 2017

Flash Debate: Registry Data and Personal Experiences Are Strong Enough to Justify Frequent Use of IMPELLA in High-Risk PCI and Cardiogenic Shock!

Presenter: Sanjay Kaul, Tullio Palmerini, Dimitri Karmpaliotis

November 01, 2017

Presentation TCT 2017

Flash Debate: There Is Insufficient Evidence From Randomized Trials to Justify Frequent Use of Impella in High-Risk PCI and Cardiogenic Shock!

Presenter: Sanjay Kaul, Tullio Palmerini, Holger Thiele

November 01, 2017

Presentation TCT 2017

Flash Debate: FFR/iFR in ACS Patients With MVD There is Little Credible Evidence on Which to Base Any Recommendations!

Presenter: Sanjay Kaul, Tullio Palmerini, Francesco Saia

November 01, 2017

Presentation TCT 2017

Flash Debate: FFR/iFR in ACS Patients With MVD - Based on the Evidence the Guidelines are Justified and Should Be Even Stronger!

Presenter: Sanjay Kaul, Tullio Palmerini, Tim P. van de Hoef

November 01, 2017

Presentation TCT 2017

Perspectives on the Feasibiity and Trustworthiness of Large, Simple Trials: From TASTE to ADAPTABLE

Presenter: Robert A. Harrington, Sanjay Kaul, Schuyler Jones

October 30, 2017

Advertisement

Rivaroxaban Offers Net Reduction in Fatal or Irreversible Events in ACS: ATLAS ACS-2 TIMI-51

Spin to Win: Results From Late-Breaking Meeting Trials Often Overstated

ISCHEMIA Fracas: Amid Charges of Moving the Goalposts, Investigators Come Out Swinging

Does IMPROVE-IT and FOURIER. Confirm or Refute the LDL Hypothesis?

Targeting Inflammation in Atherosclerosis: Has CANTOS Nailed It?

Flash Debate: Surgery Remains the First Option in All Operable Patients With Bicuspid Aortic Stenosis!

Flash Debate: Enough Evidence Is Present to Justify TAVR in Select Patients With Bicuspid Aortic Stenosis!

Flash Debate: Surveillance and Prophylactic Treatment of Asymptomatic TAVR Thrombosis Is Not Currently Warranted!

Flash Debate: Valve Thrombosis After TAVR Is a Serious Concern That Deserves Detection and Management!

Flash Debate: Based on Clinical Studies, Embolic Protection Devices Should Infrequently Be Used During TAVR

Flash Debate: The Evidence and Clinical Need Justifies the Widespread Use of Embolic Protection During TAVR

Flash Debate: Bioresorbable Scaffolds Are Appropriate for Clinical Use in Suitable Patients With Optimal Technique!

Flash Debate: Bioresorbable Scaffolds Should Rarely be Used Outside of Carefully Controlled Research Studies!

Flash Debate: If Anything, Guideline Recommendations for PCI in Low-to-Intermediate Risk Left Main Disease Should be Downgraded Based on EXCEL and NOBLE!

Flash Debate: Guideline Recommendations for PCI in Low-to-Intermediate Risk Left Main Disease Should Be Upgraded to Class I Based on EXCEL and NOBLE!

Flash Debate: Registry Data and Personal Experiences Are Strong Enough to Justify Frequent Use of IMPELLA in High-Risk PCI and Cardiogenic Shock!

Flash Debate: There Is Insufficient Evidence From Randomized Trials to Justify Frequent Use of Impella in High-Risk PCI and Cardiogenic Shock!

Flash Debate: FFR/iFR in ACS Patients With MVD There is Little Credible Evidence on Which to Base Any Recommendations!

Flash Debate: FFR/iFR in ACS Patients With MVD - Based on the Evidence the Guidelines are Justified and Should Be Even Stronger!

Perspectives on the Feasibiity and Trustworthiness of Large, Simple Trials: From TASTE to ADAPTABLE

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content